BI1265162   Click here for help

GtoPdb Ligand ID: 11717

Synonyms: BI-1265162 | example 2.04 [WO2017028927A1]
Compound class: Synthetic organic
Comment: We obtained this structure from a list compiled by DrugHunter of first time disclosures made at the 2021 XXVI EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC). The structure mapped to a PubChem entry that was submitted by SureChEMBL in 2017 as an extraction from Bohringer Ingelhiem's patent WO2017028927A1 [3]. The EFMC-ISMC discosure provided the BI1265162 name-to-structure association. BI1265162 was developed as an inhibitor of the endothelial sodium channel (ENaC), whose excessive activity in cystic fibrosis contributes to the production of hyperconcentrated mucus [5]. It is described as a 'direct inhibitor' of ENaC in a review by Mall (2020) [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 15
Topological polar surface area 164.15
Molecular weight 566.2
XLogP 2.19
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCn1c(CNC(=O)c2nc(Cl)cnc2N)[n+](c2c1cc(OCC(=O)NCCOCP(=O)(C)C)cc2)CC
Isomeric SMILES CCn1c(CNC(=O)c2nc(Cl)cnc2N)[n+](CC)c2ccc(OCC(=O)NCCOCP(=O)(C)C)cc12
InChI InChI=1S/C24H33ClN7O5P/c1-5-31-17-8-7-16(37-14-20(33)27-9-10-36-15-38(3,4)35)11-18(17)32(6-2)21(31)13-29-24(34)22-23(26)28-12-19(25)30-22/h7-8,11-12H,5-6,9-10,13-15H2,1-4H3,(H3-,26,27,28,29,33,34)/p+1
InChI Key DXVNYGRCASBPNU-UHFFFAOYSA-O
References
1. Goss CH, Fajac I, Jain R, Seibold W, Gupta A, Hsu MC, Sutharsan S, Davies JC, Mall MA. (2022)
Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
Eur Respir J, 59 (2). [PMID:34385272]
2. Goss CH, Jain R, Seibold W, Picard AC, Hsu MC, Gupta A, Fajac I. (2020)
An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1.
ERJ Open Res, 6 (4). DOI: 10.1183/23120541.00395-2020 [PMID:33313307]
3. Heckel A, Frattini S, Hamprecht D, Kley J, Wiedenmayer D. (2017)
Novel annelated phenoxyacetamides.
Patent number: WO2017028927A1. Assignee: Boehringer Ingelheim International Gmbh. Priority date: 20/08/2015. Publication date: 23/02/2017.
4. Mackie A, Rascher J, Schmid M, Endriss V, Brand T, Seibold W. (2021)
First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers.
ERJ Open Res, 7 (1). DOI: 10.1183/23120541.00447-2020 [PMID:33569494]
5. Mall MA. (2020)
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies.
Eur Respir J, 56 (6). DOI: 0.1183/13993003.00946-2020 [PMID:32732328]